FDA label
What is Namzaric used for?
Namzaric contains memantine and donepezil. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Namzaric?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Namzaric, capsule
Indications and Usage, quoted from the label by Allergan, Inc. (NDA206439). Cross-references to other label sections are left out.
NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily.
Source: DailyMed label, set id 90fedc32-19e5-480c-afc6-f35a5cf4b9aa, version 23, effective March 6, 2026. NDC 0456-1207, one of 4 listings for this product.
Questions
What is Namzaric used for?
The FDA label says: “NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily.”
What drug class is Namzaric?
FDA lists memantine and donepezil in the Cholinesterase Inhibitor and N-methyl-D-aspartate Receptor Antagonist established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.